# Article information:

VV116 versus Nirmatrelvir-Ritonavir for Oral Treatment of Covid-19 - PubMed
<https://pubmed.ncbi.nlm.nih.gov/36577095/>

# Article summary:

1. A phase 3, noninferiority, observer-blinded, randomized trial was conducted to compare the efficacy of VV116 and nirmatrelvir-ritonavir for the treatment of Covid-19.

2. The primary end point was the time to sustained clinical recovery through day 28.

3. VV116 was found to be noninferior to nirmatrelvir-ritonavir with respect to the time to sustained clinical recovery and had a lower incidence of adverse events than nirmatrelvir-ritonavir.

# Article rating:

Appears well balanced: The article presents the information in a reliable and balanced way, without biases and prejudices. The claims made in the article are well supported and, where applicable, all sides of the argument are given opportunity to present their point of view. The article appears trustworthy and reliable.

# Article analysis:

The article is generally trustworthy and reliable in its reporting of the results of the study comparing VV116 and nirmatrelvir-ritonavir for oral treatment of Covid-19. The authors provide detailed information on the methods used in their study, including how participants were selected, how they were randomized into two groups, and how outcomes were measured. The authors also provide a clear explanation of their primary end point (time to sustained clinical recovery through day 28). Furthermore, they present data from both the primary analysis and final analysis which support their conclusion that VV116 is noninferior to nirmatrelvir-ritonavir with respect to time to sustained clinical recovery.

The article does not appear to have any potential biases or one-sided reporting as it presents both sides equally and provides evidence for its claims. It does not contain any unsupported claims or missing points of consideration as all relevant information is provided in detail. Additionally, there are no unexplored counterarguments or promotional content as all arguments are presented objectively without bias towards either drug being tested. Possible risks are noted in the article as well as potential side effects associated with each drug being tested. All in all, this article appears to be trustworthy and reliable in its reporting on the comparison between VV116 and nirmatrelvir-ritonavir for oral treatment of Covid-19.

# Topics for further research:

* Covid-19 treatment efficacy
* Clinical trial design
* Randomized controlled trials
* Noninferiority trials
* Drug safety and side effects
* Clinical recovery outcomes

# Report location:

<https://www.fullpicture.app/item/b1ff485f49c3d34b2684eb67863e733e>